Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review.
Philadelphia chromosome
X chromosome
chronic myeloid leukemia
nilotinib
variant translocation
Journal
Biomedical reports
ISSN: 2049-9442
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
24
06
2018
accepted:
28
05
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
ppublish
Résumé
Chronic myeloid leukemia (CML) is characterized by the reciprocal translocation between chromosomes 9 and 22: t(9;22)(q34;q11). However, 5-10% of patients with CML have complex variant translocations involving at least a third chromosome; only a few cases affect the X chromosome. Therefore, the data available regarding their features and the response to treatment is limited. In the present report, a case of a variant Philadelphia translocation t(X;9;22)(q22?;q34;q11.2) identified in a 51-year-old female with a newly diagnosed CML is described. The patient was treated with nilotinib. A major molecular response was observed after 12 months of starting treatment. Deep molecular response was obtained 20 months later and maintained after the 110-month follow-up. Additionally, a literature review was performed, with the aim of comprehending the complex clinical and biological characteristics of CML cytogenetic variants involving the X chromosome.
Identifiants
pubmed: 34512971
doi: 10.3892/br.2021.1459
pii: BR-0-0-01459
pmc: PMC8411485
doi:
Types de publication
Case Reports
Langues
eng
Pagination
83Informations de copyright
Copyright: © Iglesias et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer Genet Cytogenet. 1988 Oct 15;35(2):179-97
pubmed: 3180020
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Acta Oncol. 2010 May;49(4):506-8
pubmed: 20331405
Blood. 2011 Jul 21;118(3):686-92
pubmed: 21536864
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Leukemia. 2015 May;29(5):999-1003
pubmed: 25652737
Leukemia. 1999 Dec;13(12):1901-28
pubmed: 10602411
Leuk Res Treatment. 2011;2011:592519
pubmed: 23213545
Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):52-59
pubmed: 27743980
Mol Cancer. 2010 May 25;9:120
pubmed: 20500819
J Assoc Genet Technol. 2019;45(2):61-65
pubmed: 31189151
Am J Hematol. 2018 Mar;93(3):442-459
pubmed: 29411417
Ann Hematol. 2015 Apr;94 Suppl 2:S107-21
pubmed: 25814077
Leukemia. 2003 Dec;17(12):2474-86
pubmed: 14562124
Cancer Genet Cytogenet. 1990 Feb;44(2):181-6
pubmed: 2297676
J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
pubmed: 9625174
Oncol Lett. 2019 Jun;17(6):5705-5710
pubmed: 31186796
J Assoc Genet Technol. 2011;37(2):69-75
pubmed: 21654069
Blood. 2011 Jun 23;117(25):6793-800
pubmed: 21447834
Leukemia. 2003 Dec;17(12):2318-57
pubmed: 14562125
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
Hereditas. 1978;89(2):207-32
pubmed: 730541
Hum Mutat. 2012 Jun;33(6):906-15
pubmed: 22415865
J Clin Med. 2020 Nov 16;9(11):
pubmed: 33207600
Haematol Blood Transfus. 1981;26:160-6
pubmed: 6947929
Cancer Genet Cytogenet. 2009 Oct;194(1):30-7
pubmed: 19737651
Ann Clin Lab Sci. 2011 Fall;41(1):71-8
pubmed: 21325259
BMC Med. 2011 Aug 26;9:99
pubmed: 21867560
Cancer Genet Cytogenet. 1994 Mar;73(1):57-9
pubmed: 8174075
J Clin Oncol. 2011 Nov 10;29(32):4260-5
pubmed: 21990394
Cancer Genet Cytogenet. 1993 Oct 15;70(2):103-7
pubmed: 8242587
Ann Hematol. 2013 Jan;92(2):185-9
pubmed: 23064942
Br J Haematol. 1979 Feb;41(2):185-91
pubmed: 284790
Blood. 1984 Apr;63(4):789-99
pubmed: 6584184
Ann Hematol. 2015 Apr;94 Suppl 2:S241-7
pubmed: 25814090
Br J Haematol. 2004 Apr;125(2):187-95
pubmed: 15059141
Cancer Genet Cytogenet. 2007 Mar;173(2):97-106
pubmed: 17321324
Br J Haematol. 1981 Apr;47(4):571-5
pubmed: 7213577